Text and Data Mining valid from 2018-11-21
Received: 4 October 2018
Accepted: 1 November 2018
First Online: 21 November 2018
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: Dr. Russell reports patents owned by the University of British Columbia (UBC) that are related to PCSK9 inhibitor(s) and sepsis and related to the use of vasopressin in septic shock. Dr. Russell is an inventor on these patents. Dr. Russell is a founder, Director, and shareholder in Cyon Therapeutics Inc. (developing a sepsis therapy (PCSK9 inhibitor)). Dr. Russell has share options in Leading Biosciences Inc. Dr. Russell is a shareholder in Molecular You Corp.Dr. Russell reports receiving consulting fees in the last 3 years from: Asahi Kesai Pharmaceuticals of America (AKPA; developing recombinant thrombomodulin in sepsis); La Jolla Pharmaceuticals (developing angiotensin II; Dr. Russell chaired the DSMB of a trial of angiotensin II from 2015 to 2017)—no longer actively consulting; Ferring Pharmaceuticals (manufactures vasopressin and was developing selepressin)—no longer actively consulting; Cubist Pharmaceuticals (now owned by Merck; formerly was Trius Pharmaceuticals; developing antibiotics)—no longer actively consulting; Leading Biosciences (was developing a sepsis therapeutic that is no longer in development)—no longer actively consulting; Grifols (sells albumin)—no longer actively consulting; CytoVale Inc. (developing a sepsis diagnostic)—no longer actively consulting.Dr. Russell reports having received an investigator-initiated grant from Grifols (entitled “Is HBP a mechanism of albumin’s efficacy in human septic shock?”) that is provided to and administered by UBC.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.